Kallikrein-related peptidase 6 exacerbates disease in an autoimmune model of multiple sclerosis

References

Angelo, P.F., Lima, A.R., Alves, F.M., Blaber, S.I., Scarisbrick, I.A., Blaber, M., Juliano, L., and Juliano, M.A. (2006). Substrate specificity of human kallikrein 6: salt and glycosaminoglycan activation effects. J. Biol. Chem. 281, 3116–3126.10.1074/jbc.M510096200Search in Google Scholar

Bar-Or, A. (2016). Multiple sclerosis and related disorders: evolving pathophysiologic insights. Lancet Neurol. 15, 9–11.10.1016/S1474-4422(15)00342-7Search in Google Scholar

Bernett, M.J., Blaber, S.I., Scarisbrick, I.A., Dhanarajan, P., Thompson, S.M., and Blaber, M. (2002). Crystal structure and biochemical characterization of human kallikrein 6 reveals that a trypsin-like kallikrein is expressed in the central nervous system. J. Biol. Chem. 277, 24562–24570.10.1074/jbc.M202392200Search in Google Scholar PubMed

Blaber, S.I., Scarisbrick, I.A., Bernett, M.J., Dhanarajan, P., Seavy, M.A., Jin, Y., Schwartz, M.A., Rodriguez, M., and Blaber, M. (2002). Enzymatic properties of rat myelencephalon-specific protease. Biochemistry 41, 1165–1173.10.1021/bi015781aSearch in Google Scholar PubMed

Blaber, S.I., Ciric, B., Christophi, G.P., Bernett, M.J., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Targeting kallikrein 6-proteolysis attenuates CNS inflammatory disease. FASEB J. 19, 920–922.10.1096/fj.03-1212fjeSearch in Google Scholar PubMed

Burda, J.E., Radulovic, M., Yoon, H., and Scarisbrick, I.A. (2013). Critical role for PAR1 in kallikrein 6-mediated oligodendrogliopathy. Glia 61, 1456–1470.10.1002/glia.22534Search in Google Scholar PubMed PubMed Central

Christophi, G.P., Isackson, P.J., Blaber, S.I., Blaber, M., Rodriguez, M., and Scarisbrick, I.A. (2004). Distinct promoters regulate tissue-specific and differential expression of kallikrein 6 in CNS demyelinating disease. J. Neurochem. 91, 1439–1449.10.1111/j.1471-4159.2004.02826.xSearch in Google Scholar PubMed

Ferber, I.A., Brocke, S., Taylor-Edwards, C., Ridgway, W., Dinisco, C., Steinman, L., Dalton, D., and Fathman, C.G. (1996). Mice with disrupted IFN-γ gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J. Immunol. 156, 5–7.10.4049/jimmunol.156.1.5Search in Google Scholar

Guo, S., Skala, W., Magdolen, V., Brandstetter, H., and Goettig, P. (2014). Sweetened kallikrein-related peptidases (KLKs): glycan trees as potential regulators of activation and activity. Biol. Chem. 395, 959–976.10.1515/hsz-2014-0140Search in Google Scholar PubMed

Hebb, A.L., Bhan, V., Wishart, A.D., Moore, C.S., and Robertson, G.S. (2011). Human kallikrein 6 cerebrospinal levels are elevated in multiple sclerosis. Curr. Drug. Discov. Technol. 7, 137–140.10.2174/157016310793180611Search in Google Scholar PubMed

Komiyama, Y., Nakae, S., Matsuki, T., Nambu, A., Ishigame, H., Kakuta, S., Sudo, K., and Iwakura, Y. (2006). IL-17 plays an important role in the development of experimental autoimmune encephalomyelitis. J. Immunol. 177, 566–573.10.4049/jimmunol.177.1.566Search in Google Scholar PubMed

Kruglov, A.A., Lampropoulou, V., Fillatreau, S., and Nedospasov, S.A. (2011). Pathogenic and protective functions of TNF in neuroinflammation are defined by its expression in T lymphocytes and myeloid cells. J. Immunol. 187, 5660–5670.10.4049/jimmunol.1100663Search in Google Scholar PubMed

Kruisbeek, A.M., Shevach, E., and Thornton, A.M. (2004). Proliferative assays for T cell function. Curr. Protoc. Immunol. Chapter 3, Unit 3. 12.10.1002/0471142735.im0312s60Search in Google Scholar PubMed

Kuzmanov, U., Jiang, N., Smith, C.R., Soosaipillai, A., and Diamandis, E.P. (2009). Differential N-glycosylation of kallikrein 6 derived from ovarian cancer cells or the central nervous system. Mol. Cell Proteomics. 8, 791–798.10.1074/mcp.M800516-MCP200Search in Google Scholar PubMed PubMed Central

Liblau, R., Steinman, L., and Brocke, S. (1997). Experimental autoimmune encephalomyelitis in IL-4-deficient mice. Int. Immunol. 9, 799–803.10.1093/intimm/9.5.799Search in Google Scholar PubMed

McCarthy, D.P., Richards, M.H., and Miller, S.D. (2012). Mouse models of multiple sclerosis: experimental autoimmune encephalomyelitis and Theiler’s virus-induced demyelinating disease. Methods Mol. Biol. 900, 381–401.10.1007/978-1-60761-720-4_19Search in Google Scholar PubMed PubMed Central

Miller, S.D., Karpus, W.J., and Davidson, T.S. (2010). Experimental autoimmune encephalomyelitis in the mouse. Curr. Protoc. Immunol. Chapter 15, Unit 15. 1.10.1002/0471142735.im1501s88Search in Google Scholar PubMed

Nylander, A. and Hafler, D.A. (2012). Multiple sclerosis. J. Clin. Invest. 122, 1180–1188.10.1172/JCI58649Search in Google Scholar PubMed PubMed Central

Oikonomopoulou, K., Hansen, K.K., Saifeddine, M., Tea, I., Blaber, M., Blaber, S.I., Scarisbrick, I., Andrade-Gordon, P., Cottrell, G. S., Bunnett, N.W., et al. (2006). Proteinase-activated receptors, targets for kallikrein signaling. J. Biol. Chem. 281, 32095–32112.10.1074/jbc.M513138200Search in Google Scholar PubMed

Panos, M., Christophi, G.P., Rodriguez, M., and Scarisbrick, I.A. (2014). Differential expression of multiple kallikreins in a viral model of multiple sclerosis points to unique roles in the innate and adaptive immune response. Biol. Chem. 395, 1063–1073.10.1515/hsz-2014-0141Search in Google Scholar PubMed PubMed Central

Radulovic, M., Yoon, H., Larson, N., Wu, J., Linbo, R., Burda, J.E., Diamandis, E.P., Blaber, S.I., Blaber, M., Fehlings, M.G., et al. (2013). Kallikrein cascades in traumatic spinal cord injury: in vitro evidence for roles in axonopathy and neuron degeneration. J. Neuropathol. Exp. Neurol. 72, 1072–1089.10.1097/NEN.0000000000000007Search in Google Scholar PubMed PubMed Central

Radulovic, M., Yoon, H., Wu, J., Mustafa, K., Fehlings, M.G., and Scarisbrick, I.A. (2015). Genetic targeting of protease activated receptor 2 reduces inflammatory astrogliosis and improves recovery of function after spinal cord injury. Neurobiol. Dis. 83, 75–89.10.1016/j.nbd.2015.08.021Search in Google Scholar

Radulovic, M., Yoon, H., Wu, J., Mustafa, K., and Scarisbrick, I.A. (2016). Targeting the thrombin receptor modulates inflammation and astrogliosis to improve recovery after spinal cord injury. Neurobiol. Dis. 93, 226–242.10.1016/j.nbd.2016.04.010Search in Google Scholar

Ransohoff, R.M., Hafler, D.A., and Lucchinetti, C.F. (2015). Multiple sclerosis-a quiet revolution. Nat. Rev. Neurol. 11, 134–142.10.1038/nrneurol.2015.14Search in Google Scholar

Scarisbrick, I.A. (2008). The multiple sclerosis degradome: enzymatic cascades in development and progression of central nervous system inflammatory disease. Curr. Top. Microbiol. Immunol. 318, 133–175.10.1007/978-3-540-73677-6_6Search in Google Scholar

Scarisbrick, I.A. and Blaber, M. (2012). Kallikrein-related peptidase 6. In: Handbook of Proteolytic Enzymes. A. J. Barrett and N.D. Rawlings, eds. (London, UK, Elsevier), pp. 2780–2786.10.1016/B978-0-12-382219-2.00612-8Search in Google Scholar

Scarisbrick, I.A., Towner, M.D., and Isackson, P.J. (1997). Nervous system specific expression of a novel serine protease: regulation in the adult rat spinal cord by excitotoxic injury. J. Neurosci. 17, 8156–8168.10.1523/JNEUROSCI.17-21-08156.1997Search in Google Scholar

Scarisbrick, I.A., Asakura, K., Blaber, S., Blaber, M., Isackson, P.J., Beito, T., Rodriguez, M., and Windebank, A.J. (2000). Preferential expression of myelencephalon specific protease by oligodendrocytes of the adult rat spinal cord white matter. Glia 30, 219–230.10.1002/(SICI)1098-1136(200005)30:3<219::AID-GLIA2>3.0.CO;2-2Search in Google Scholar

Scarisbrick, I.A., Isackson, P.J., Ciric, B., Windebank, A.J., and Rodriguez, M. (2001). MSP, a trypsin-like serine protease, is abundantly expressed in the human nervous system. J. Comp. Neurol. 431, 347–361.10.1002/1096-9861(20010312)431:3<347::AID-CNE1075>3.0.CO;2-KSearch in Google Scholar

Scarisbrick, I.A., Blaber, S.I., Lucchinetti, C.F., Genain, C.P., Blaber, M., and Rodriguez, M. (2002). Activity of a newly identified serine protease in CNS demyelination. Brain 125, 1283–1296.10.1093/brain/awf142Search in Google Scholar

Scarisbrick, I.A., Blaber, S.I., Tingling, J.T., Rodriguez, M., Blaber, M., and Christophi, G.P. (2006a). Potential scope of action of tissue kallikreins in CNS immune-mediated disease. J. Neuroimmunol. 178, 167–176.10.1016/j.jneuroim.2006.05.022Search in Google Scholar

Scarisbrick, I.A., Sabharwal, P., Cruz, H., Larsen, N., Vandell, A., Blaber, S.I., Ameenuddin, S., Papke, L.M., Fehlings, M.G., Reeves, R.K., et al. (2006b). Dynamic role of kallikrein 6 in traumatic spinal cord injury. Eur. J. Neuroscience 24, 1457–1469.10.1111/j.1460-9568.2006.05021.xSearch in Google Scholar

Scarisbrick, I.A., Linbo, R., Vandell, A.G., Keegan, M., Blaber, S.I., Blaber, M., Sneve, D., Lucchinetti, C. F., Rodriguez, M., and Diamandis, E.P. (2008). Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration. Biol. Chem. 389, 739–745.10.1515/BC.2008.085Search in Google Scholar PubMed PubMed Central

Scarisbrick, I.A., Epstein, B., Cloud, B.A., Yoon, H., Wu, J., Renner, D.N., Blaber, S.I., Blaber, M., Vandell, A. G., and Bryson, A.L. (2011). Functional role of kallikrein 6 in regulating immune cell survival. PLoS One 6, e18376; 18371–18311.10.1371/journal.pone.0018376Search in Google Scholar PubMed PubMed Central

Scarisbrick, I.A., Radulovic, M., Burda, J.E., Larson, N., Blaber, S.I., Giannini, C., Blaber, M., and Vandell, A.G. (2012a). Kallikrein 6 is a novel molecular trigger of reactive astrogliosis. Biol. Chem. 393, 355–367.10.1515/hsz-2011-0241Search in Google Scholar PubMed PubMed Central

Scarisbrick, I.A., Yoon, H., Panos, M., Larson, N., Blaber, S. I., Blaber, M., and Rodriguez, M. (2012b). Kallikrein 6 regulates early CNS demyelination in a viral model of multiple sclerosis. Brain Pathol. 22, 709–722.10.1111/j.1750-3639.2012.00577.xSearch in Google Scholar PubMed PubMed Central

Schutzer, S.E., Angel, T.E., Liu, T., Schepmoes, A.A., Xie, F., Bergquist, J., Vecsei, L., Zadori, D., Camp, D.G., 2nd, Holland, B.K., et al. (2013). Gray matter is targeted in first-attack multiple sclerosis. PLoS One 8, e66117.10.1371/journal.pone.0066117Search in Google Scholar PubMed PubMed Central

Singh, V., van Pelt, E.D., Stoop, M.P., Stingl, C., Ketelslegers, I.A., Neuteboom, R.F., Catsman-Berrevoets, C.E., Luider, T.M., and Hintzen, R.Q. (2015). Gray matter-related proteins are associated with childhood-onset multiple sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2, e155.10.1212/NXI.0000000000000155Search in Google Scholar PubMed PubMed Central

Vandell, A.G., Larson, N., Laxmikanthan, G., Panos, M., Blaber, S.I., Blaber, M., and Scarisbrick, I.A. (2008). Protease activated receptor dependent and independent signaling by kallikreins 1 and 6 in CNS neuron and astroglial cell lines. J. Neurochem. 107, 855–870.10.1111/j.1471-4159.2008.05658.xSearch in Google Scholar PubMed PubMed Central

Yoon, H., Radulovic, M., Wu, J., Blaber, S.I., Blaber, M., Fehlings, M.G., and Scarisbrick, I.A. (2013). Kallikrein 6 signals through PAR1 and PAR2 to promote neuron injury and exacerbate glutamate neurotoxicity. J. Neurochem. 127, 283–298.10.1111/jnc.12293Search in Google Scholar PubMed PubMed Central

Yoon, H., Radulovic, M., Drucker, K. L., Wu, J., and Scarisbrick, I.A. (2015). The thrombin receptor is a critical extracellular switch controlling myelination. Glia 63, 846–859.10.1002/glia.22788Search in Google Scholar PubMed PubMed Central